---
title: "Liquid Biopsy and MRD"
canonical_url: "https://www.newpathology.de/#biomarkers"
language: "en"
site: "New Pathology"
---
# Liquid Biopsy and MRD

Experience spans tissue-based and blood-based oncology biomarker assays, including DNA, RNA, and protein-level technologies. This includes next-generation sequencing oncology, immunohistochemistry biomarkers, and liquid biopsy diagnostics across solid tumors.

## Genomic technologies (liquid biopsy and MRD)

- Liquid biopsy diagnostics and ctDNA (circulating tumor DNA) testing strategies, from feasibility to routine clinical adoption.
- Minimal residual disease (MRD (measurable/minimal residual disease)) analysis in solid tumors, including the design and interpretation of tumor-informed MRD (measurable/minimal residual disease) assays and longitudinal monitoring concepts.

## Liquid Biopsy & MRD

- Liquid biopsy diagnostics and ctDNA (circulating tumor DNA) testing strategies
- Analytical and clinical aspects of ctDNA (circulating tumor DNA) assays
- Minimal residual disease (MRD (measurable/minimal residual disease)) analysis in solid tumors and tumor-informed MRD (measurable/minimal residual disease) assays
- Use of MRD (measurable/minimal residual disease) readouts in clinical trials and routine care
- Positioning of liquid biopsy in existing pathology workflows

Related HTML: [Biomarkers & Technologies](https://www.newpathology.de/#biomarkers)